Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
BIOC-11 is under development for the treatment of bronchiectasis caused by Pseudomonas aeruginosa and cystic fibrosis. This candidate is formulated as an isotonic, buffered aqueous solution for oral ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...
Researchers at National Jewish Health and colleagues have completed the first study comparing lung macrophages in multiple ...
In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global leader in cystic fibrosis (CF) treatments. CF is a genetic ...
A llison Angell, the first UK patient to have all of her major organs transplanted, has died aged 46. Allison, who suffered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback